Project 2 Fetuin-A in Prostate Cancer
项目 2 胎球蛋白-A 在前列腺癌中的应用
基本信息
- 批准号:10705093
- 负责人:
- 金额:$ 22.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-26 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAKT Signaling PathwayAblationAddressAffectAfrican AmericanAmericanAndrogensAttenuatedBiogenesisCancer EtiologyCaucasiansCellsCessation of lifeDataDeath RateDiseaseDisease OutcomeDoctor of PhilosophyEnterobacteria phage P1 Cre recombinaseFemaleFreezingGenerationsGenesGleason Grade for Prostate CancerGlycoproteinsGrowthHumanImmunohistochemistryIn VitroIndolentInvadedKnock-outKnockout MiceLNCaPLaboratoriesLinear RegressionsLiverMalignant neoplasm of prostateMediatingMessenger RNAMitogen-Activated Protein KinasesModelingMolecularMusMutant Strains MiceNeoplasm MetastasisNull LymphocytesPIK3CG genePTEN genePatient-Focused OutcomesPatientsPharmaceutical PreparationsPlayProcessProductionPrognosisPrognostic MarkerProstateProstate Cancer therapyProstatic NeoplasmsProteinsProto-Oncogene Proteins c-aktPubertyRefractoryRegression AnalysisResearch PersonnelRoleSerumSignal PathwaySignal TransductionTLR4 geneThe Vanderbilt-Ingram Cancer Center at the Vanderbilt UniversityTissuesTransfectionTumor VolumeWestern BlottingXenograft procedurealpha-Fetoproteinsbiomarker identificationcalcificationcancer health disparitycancer initiationcancer preventioncastration resistant prostate cancercaucasian Americancell growthcell motilityexosomeexperimental studyin vivomRNA Expressionmalemenmortalitymouse modelmutantnano-stringnanovesicleoverexpressionparticleprobasinprostate cancer cellprostate cancer cell lineprostate cancer modelprostate cancer progressiontransmission processtumortumor growthtumor initiationtumor progressiontumorigenicuptake
项目摘要
PROJECT SUMMARY: FULL PROJECT 2
Even though the growth of prostate cancer (PCa) is largely driven by androgens, a subset usually develops that
is refractory to androgen ablation (also known as castration resistant PCa; CRPC) with potential for metastasis.
Preliminary data from our laboratory has implicated fetuin-A, also known as alpha 2-Heremans-Schmid
glycoprotein (AHSG), in the growth of PCa cells and in the production of “uptake-competent” exosomes. The
objective of the proposed studies is to define the role and significance of fetuin-A in prostate cancer progression.
We hypothesize that PCa cells express ectopic fetuin-A which is secreted and taken up by the cells via TLR4 to
mediate the biogenesis of `uptake-competent' exosomes that promote PCa growth via activation of pAKT/pERK;
moreover, we postulate that elevated fetuin-A expression serves as a prognostic biomarker for PCa. Three
specific aims are proposed: Aim 1. To determine if fetuin-A expression is higher in AA PCa tissues relative
to Caucasian American (CA) PCa tissues and whether high fetuin-A expression is associated with high
Gleason Scores (>6) and enhanced pAKT and pERK. We will analyze mRNA expression of fetuin-A using
NanoString as well as pAKT/pERK protein levels using immunohistochemistry (IHC) analysis of human PCa
tissues. Multivariable linear regression analysis will be used to determine the correlation between fetuin-A, pAKT,
pERK and Gleason scores in PCa tissues of AA and CA patients, as well as other progression parameters such
as positive margins and spread of PCa. It is expected that fetuin-A, pAKT and pERK will be expressed at high
levels in PCa tissues of AA patients particularly those with high Gleason scores (>6). Aim 2. To determine the
role of ectopic fetuin-A in exosome biogenesis, promotion of 2-D and 3-D growth, motility and invasive
capacity of PCa cells. In this aim, we will overexpress and knockout fetuin-A in two PCa cell lines to determine
whether fetuin-A plays a causal role in the biogenesis of `uptake competent' exosomes that transmit growth
signals in recipient cells. We expect to demonstrate that exosomes from fetuin-A overexpressing cells will
promote 2-D, 3-D growth and motility and invasion of PCa cells while exosomes from fetuin-A null cells will not.
Aim 3. To investigate the efficacy of targeting fetuin-A mediated signaling on the suppression of prostate
tumor initiation and growth in mice. In this aim, we will utilize the Pten-null mouse model for PCa to determine
whether Pten loss requires intact fetuin-A gene to mediate its tumorigenic role and whether loss of fetuin-A in
Pten-/-/fetuin-A-/- double mutant mice attenuates the tumorigenic role of Pten-null. We expect reduced tumor
growth in the double mutant mice compared to Pten-null fetuin-A+/+ mice. Significance: There is an urgent need
to identify biomarkers that can differentiate CRPC from indolent PCa and this proposal addresses that need and
evaluates the process by which fetuin-A enhances PCa tumor growth.
项目摘要:完整项目 2
尽管前列腺癌 (PCa) 的生长主要是由雄激素驱动的,但其中一部分通常会发展为
对雄激素消融有抵抗力(也称为去势抵抗性 PCa;CRPC),具有转移潜力。
我们实验室的初步数据表明胎球蛋白-A,也称为 α 2-Heremans-Schmid
糖蛋白(AHSG),在 PCa 细胞的生长和“具有摄取能力”的外泌体的产生中。这
拟议研究的目的是确定胎球蛋白-A 在前列腺癌进展中的作用和意义。
我们假设 PCa 细胞表达异位胎球蛋白-A,该细胞通过 TLR4 分泌并摄取
介导“具有摄取能力”外泌体的生物发生,通过激活 pAKT/pERK 促进 PCa 生长;
此外,我们假设胎球蛋白-A 表达升高可作为 PCa 的预后生物标志物。三
提出了具体目标: 目标 1. 确定 AA PCa 组织中胎球蛋白 A 的表达是否相对较高
与高加索裔美国人 (CA) PCa 组织的关系以及高胎球蛋白 A 表达是否与高
格里森评分 (>6) 和增强的 pAKT 和 pERK。我们将使用以下方法分析胎球蛋白-A 的 mRNA 表达
使用人类 PCa 的免疫组织化学 (IHC) 分析 NanoString 以及 pAKT/pERK 蛋白水平
组织。多变量线性回归分析将用于确定胎球蛋白-A、pAKT、
AA 和 CA 患者 PCa 组织中的 pERK 和 Gleason 评分,以及其他进展参数,例如
作为正利润率和 PCa 的传播。预计胎球蛋白-A、pAKT 和 pERK 将高表达
AA 患者的 PCa 组织中的水平,特别是那些格里森评分高 (>6) 的患者。目标 2. 确定
异位胎球蛋白-A 在外泌体生物合成、促进 2-D 和 3-D 生长、运动性和侵袭性中的作用
PCa 细胞的容量。为此,我们将在两种 PCa 细胞系中过表达并敲除胎球蛋白-A,以确定
胎球蛋白-A是否在传递生长的“摄取能力”外泌体的生物发生中发挥因果作用
受体细胞中的信号。我们期望证明来自胎球蛋白-A 过表达细胞的外泌体将
促进 PCa 细胞的 2-D、3-D 生长、运动和侵袭,而来自胎球蛋白 A 缺失细胞的外泌体则不会。
目标 3. 研究靶向胎球蛋白 A 介导的信号传导对前列腺抑制的功效
小鼠肿瘤的发生和生长。为此,我们将利用 PCa 的 Pten-null 小鼠模型来确定
Pten 缺失是否需要完整的胎球蛋白 A 基因来介导其致瘤作用以及胎球蛋白 A 的缺失是否
Pten-/-/fetuin-A-/- 双突变小鼠减弱了 Pten-null 的致瘤作用。我们预计肿瘤会减少
与 Pten-null 胎球蛋白-A+/+ 小鼠相比,双突变小鼠的生长情况。意义:迫切需要
以确定可以区分 CRPC 和惰性 PCa 的生物标志物,该提案解决了这一需求并
评估胎球蛋白-A 增强 PCa 肿瘤生长的过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSIAH OCHIENG其他文献
JOSIAH OCHIENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSIAH OCHIENG', 18)}}的其他基金
Analysis of Serum Exsomes in Patients with Colorectal and Breast Cancer
结直肠癌和乳腺癌患者血清外泌体分析
- 批准号:
8261513 - 财政年份:2011
- 资助金额:
$ 22.57万 - 项目类别:
INTEGRIN ACTIVITIES DURING TUMOR PROGRESSION BY GALECTIN-3
Galectin-3 在肿瘤进展过程中的整合素活性
- 批准号:
6485272 - 财政年份:2001
- 资助金额:
$ 22.57万 - 项目类别:
相似海外基金
Myocardial preconditioning effects of amino acids and PI3K/Akt signaling pathway
氨基酸和PI3K/Akt信号通路的心肌预适应作用
- 批准号:
16K10955 - 财政年份:2016
- 资助金额:
$ 22.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Myocardial preconditioning effects of high-dose insulin and PI3K/Akt signaling pathway
大剂量胰岛素及PI3K/Akt信号通路对心肌的预处理作用
- 批准号:
25462429 - 财政年份:2013
- 资助金额:
$ 22.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Functional analysis of the PI3K/Akt signaling pathway during the mammalian inner ear development and its application for regenerative medicine
哺乳动物内耳发育过程中PI3K/Akt信号通路的功能分析及其在再生医学中的应用
- 批准号:
23592496 - 财政年份:2011
- 资助金额:
$ 22.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of regulatory mechanism of PI3K-Akt signaling pathway by TTC3
TTC3对PI3K-Akt信号通路的调控机制分析
- 批准号:
22770118 - 财政年份:2010
- 资助金额:
$ 22.57万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
8003647 - 财政年份:2009
- 资助金额:
$ 22.57万 - 项目类别:
Molecular Therapy Targeting PTEN-Akt Signaling Pathway in Prostate Cancer.
前列腺癌中针对 PTEN-Akt 信号通路的分子治疗。
- 批准号:
17591697 - 财政年份:2005
- 资助金额:
$ 22.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
7525551 - 财政年份:2002
- 资助金额:
$ 22.57万 - 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
7645586 - 财政年份:2002
- 资助金额:
$ 22.57万 - 项目类别:
Gq-Coupled Receptors Inhibit PI 3-Kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
8064263 - 财政年份:2002
- 资助金额:
$ 22.57万 - 项目类别:
Gq-Coupled Receptors Inhibit PI 3-Kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
- 批准号:
8274809 - 财政年份:2002
- 资助金额:
$ 22.57万 - 项目类别:














{{item.name}}会员




